Merck (MRK) reportedly in talks to acquire Revolution Medicines (RVMD) for USD 30bln, according to WSJ

Merck’s reported talks to acquire Revolution Medicines for $30 billion indicate a significant move within the pharmaceuticals sector, potentially positioning Merck to enhance its oncology portfolio.

Newsquawk StaffPublished On the live feed at 2 more headlines followed before this page went public
Newsquawk headlinesUTC

US Commerce Dept. drops plan to impose restrictions on Chinese-made drones, according to a filing

US President Trump says they are getting along well with the interim government in Venezuela

Merck (MRK) reportedly in talks to acquire Revolution Medicines (RVMD) for USD 30bln, according to WSJ

US President Trump says the US, in coordination with Venezuela, seized an oil tanker which departed Venezuela without approval; the oil will be sold through the energy deal they have created

White House says it is reviewing protocols regarding economic data releases; says there was an inadvertent public disclosure of aggregate data that was partially derived from pre-released information

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

If successful, this acquisition could affect market perceptions of Merck's growth trajectory and influence investor sentiment across related biotech stocks. Watch for implications on capital allocation and Merck’s ability to integrate the acquired assets effectively.

Related headlines

The whole workspace, free to try.

Try it free